A- 1 Note: The Company issued the A- 1 Note with a stated principal amount of $ 10.93 million, inclusive of an original issue discount ("OID") of $ 0.9 million and a $ 30,000 transaction expense reimbursement to the lender to cover the lender’s legal, accounting and due diligence expenses.

filing / Aug 14, 2026 / receipt

The A-1 Note had an initial stated principal amount of approximately $10.93 million, including an original issue discount and transaction-expense reimbursement, bears interest at 9% per annum compounded daily and matures on September 2, 2027.

filing / Aug 14, 2026 / receipt

We expect our general and administrative expenses to increase for the foreseeable future due to anticipated increases in headcount to advance stenoparib and as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the SEC, Nasdaq, additional insurance expenses, investor relations activities and other administrative and professional services.

filing / Aug 14, 2026 / receipt

Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of June 30, 2026.

filing / Aug 14, 2026 / receipt

A- 1 Note (Unsecured): The Company issued the A- 1 Note with a stated principal amount of $ 10.93 million, inclusive of an original issue discount ("OID") $ 0.9 million and a $ 30,000 transaction expense reimbursement to the lender to cover the lender’s legal, accounting and due diligence expenses.

filing / May 15, 2026 / receipt

We expect our general and administrative expenses to increase for the foreseeable future due to anticipated increases in headcount to advance stenoparib and as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the SEC, Nasdaq, additional insurance expenses, investor relations activities and other administrative and professional services.

filing / May 15, 2026 / receipt

Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of March 31, 2026.

filing / May 15, 2026 / receipt